The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1385
March 5, 2012
View Complete Issue         Table of Contents 2019 
Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension
March 5, 2012 (Issue: 1385)
The FDA has approved a fixed-dose combination of the angiotensin receptor blocker (ARB) azilsartan and the thiazide-like diuretic chlorthalidone as Edarbyclor (Takeda) for treatment of hypertension
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension
Article code: 1385a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.